Tyrosine kinase inhibitorFDA-approvedSecond-line
Gilteritinib
How it works
Blocks the FLT3 tyrosine kinase enzyme, which is involved in the growth and survival of cancer cells.
Cancer types
Leukemia— FLT3-ITD-positive AML
Efficacy
Studies show that around 50% of patients with FLT3-mutated AML achieved a complete remission, with a median overall survival of approximately 9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Gilteritinib Therapy After Transplantation for High-Risk AML Patients | Leukemia | meta-analysis | 1- and 2-year overall survival rates ranged from 72.3% to 100% and 55.8% to 60.0%, respectively. | Source → |
| Gilteritinib May Help Treat Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| New Cancer Treatment Shows Promise with Low Heart Damage | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.